Venn Life Sciences Holdings Stock London S.E.
Equities
GB00B9275X97
Biotechnology & Medical Research
Sales 2023 | 56.04M 70.17M 95.94M | Sales 2024 * | 62.91M 78.77M 108M | Capitalization | 189M 237M 324M |
---|---|---|---|---|---|
Net income 2023 | 16M 20.03M 27.39M | Net income 2024 * | 8M 10.02M 13.7M | EV / Sales 2023 | 2.88 x |
Net cash position 2023 * | 34.79M 43.56M 59.56M | Net cash position 2024 * | 43.8M 54.85M 74.99M | EV / Sales 2024 * | 2.31 x |
P/E ratio 2023 |
10.1
x | P/E ratio 2024 * |
22.3
x | Employees | - |
Yield 2023 * |
1.46% | Yield 2024 * |
0.85% | Free-Float | 60.77% |
Latest transcript on Venn Life Sciences Holdings
Managers | Title | Age | Since |
---|---|---|---|
Yamin Khan
CEO | Chief Executive Officer | 55 | 21-10-12 |
Ian O'Connell
FOU | Founder | 37 | 11-01-31 |
Cathal Friel
FOU | Founder | 59 | 11-01-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 57 | 22-06-07 | |
Cathal Friel
FOU | Founder | 59 | 11-01-31 |
Brendan Buckley
FOU | Founder | 73 | 18-11-30 |
1st Jan change | Capi. | |
---|---|---|
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |